Press release content from Globe Newswire. The AP news staff was not involved in its creation.
DeepVerge PLC: Microtox® BT Evaluation of SARS-CoV-2 from breath test with Clinical Samples
Deepverge PLCMarch 17, 2021 GMT
YORK, United Kingdom, March 17, 2021 (GLOBE NEWSWIRE) DeepVerge (LSE:DVRG.L), the environmental and life science AI company, announces initial data for ongoing Phase III clinical studies on the detection of SARS-CoV-2 on breath samples and identification of confirmed COVID19 positive patients .
Since Q3 2020, DeepVerge scientists have been working under laboratory conditions with the Spike Protein (“S-Protein”) of SARS-CoV-2 on the SARS-CoV-2 virus inside the Containment Level 3 (“CL3″) laboratories at the University of Aberdeen. In these studies, they have detected and identified the virus S-Protein in quantities at 40 femtogram[i] per millilitre (“Fg/mL”) at close to 100% sensitivity and specificity on DeepVerge’s Microtox® BT[ii] nano